Metabolic Diseases
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies
Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership
Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases
Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
OrsoBio Secures $67 Million in Funding for Next-Generation Obesity Treatments
OrsoBio, obesity drugs, Eli Lilly, Series B funding, weight loss medicines, metabolic disorders
Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment
Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition
Novo Nordisk and Metaphore Pharmaceuticals Join Forces in a $600 Million Partnership to Pioneer Innovative Obesity Treatments
Novo Nordisk, Metaphore Pharmaceuticals, obesity drugs, next-generation treatments, $600 million deal, partnership, pharmaceutical collaboration, weight loss medications, metabolic disorders.
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.